Skip Navigation

European Heart Journal 2003 24(14):1296-1303; doi:10.1016/S0195-668X(03)00202-1
Copyright © 2003 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Matsuo, H.
Right arrow Articles by Fujiwara, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsuo, H.
Right arrow Articles by Fujiwara, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Regular Articles

Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil

Hitoshi Matsuoa,*, Sachiro Watanabea, Tomonori Segawaa, Shinji Yasudaa, Takeshi Hirosea, Makoto Iwamaa, Shinichiro Tanakaa, Takahiko Yamakia, Yukihiko Matsunoa, Masaaki Tomitaa, Shinya Minatoguchib and Hisayoshi Fujiwarab,*

a Gifu Prefectural Hospital, Gifu, Japan
b The Second Department of Internal Medicine, Gifu University School of Medicine, Gifu, Japan

* Correspondence to: Hitoshi Matsuo MD, 4-6-1, Noishiki, Gifu City, Gifu Prefecture, 500, Japan. Tel: 81-58-246-1111; fax: 81-58-248-3805

E-mail address: matsuo{at}iri.rd.pref.gifu.jp

Received 2 November 2002; revised 13 February 2003; accepted 5 March 2003

Background It is not known whether pretreatment with nicorandil, an ATP-sensitive K+ channel (KATPchannel) opener, induces a preconditioning effect independent of increased collateral recruitment.

Methods Forty-four patients with angina who underwent percutaneous transluminal coronary angioplasty (PTCA) to proximal left anterior descending artery (LAD) stenosis were randomly allocated for pretreatment with an intravenous injection of 80g/kg nicorandil 5min before initial ballooning (n=22) or saline (n=22). 99mTc tetrofosmin was injected during balloon inflation, quantitative analysis of occlusion images by SPECT was conducted, and the defect severity score (SS) was calculated. An ECG was recorded during the 2-min inflation to calculate the sum of ST elevation ({Sigma}ST).

Results {Sigma}ST levels were significantly reduced in patients with nicorandil pretreatment compared with control patients (control:1.89±0.85mV nicorandil:1.24±0.57mV, p=0.0052). However, no difference was observed in defect severity (control: 79.0±32.5, nicorandil: 98.7±48.9 ns). A close correlation was observed between SS and {Sigma}ST in both groups (nicorandil group R2=0.505, control group R2=0.599). A multivariate regression model demonstrated that both defect severity (p<0.0001) and pretreatment with nicorandil (p<0.001) were significantly related to the level of {Sigma}ST, suggesting a cellular protective effect against ischaemia by nicorandil, independent of myocardial blood flow.

Conclusion Nicorandil pretreatment resulted in the induction of myocardial preconditioning independent of the severity of ischaemia.

Key Words: Angina pectoris • K+ channel opener • Ischemic preconditioning • Coronary angioplasty • Radionuclide imaging


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Nicorandil: a drug for many purposes: too good to be true?
Eric Eeckhout
EHJ 2003 24: 1282-1284. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
Eur Heart JHome page
Y. Kawai, K. Hisamatsu, H. Matsubara, K. Dan, S. Akagi, K. Miyaji, M. Munemasa, Y. Fujimoto, K. F. Kusano, and T. Ohe
Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon
Eur. Heart J., April 1, 2009; 30(7): 765 - 772.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
A. G. Herman and S. Moncada
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis
Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. Schalla, C. B. Higgins, M. Chujo, and M. Saeed
Effect of Potassium-Channel Opener Therapy on Reperfused Infarction in Hypertrophied Hearts: Demonstration of Preconditioning by Using Functional and Contrast-Enhanced Magnetic Resonance Imaging
Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 193 - 202.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X.-L. Tang, Y.-T. Xuan, Y. Zhu, G. Shirk, and R. Bolli
Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits
Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1273 - H1280.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
E. Eeckhout
Nicorandil: a drug for many purposes: too good to be true?
Eur. Heart J., July 2, 2003; 24(14): 1282 - 1284.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.